Replimune Group, Inc. (REPL) Financials

REPL Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 252.4 million 146.8 million
March 31, 2026 332.4 million 166.2 million
Dec. 31, 2025 333.6 million 123.1 million
Sept. 30, 2025 389.5 million 126.1 million

REPL Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -75.7 million 7.7 million
March 31, 2026 -56.2 million 8.1 million
Dec. 31, 2025 -66.1 million 7.0 million
Sept. 30, 2025 -82.6 million 8.3 million

REPL Net Income

No data available :(

REPL Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 195.3 million 23.8 million -
March 31, 2026 268.9 million 83.3 million 28.3 million
Dec. 31, 2025 269.1 million 47.6 million 28.7 million
Sept. 30, 2025 323.6 million 47.2 million 29.1 million

REPL Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 96.9 million
March 31, 2026 92.8 million
Dec. 31, 2025 92.2 million
Sept. 30, 2025 91.9 million

REPL Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 6000 49.3 million 19.0 million -
March 31, 2026 5000 52.3 million 53.6 million -
Dec. 31, 2025 135000 53.1 million 18.7 million -
Sept. 30, 2025 1.3 million 57.9 million 26.4 million -

REPL Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - -
Dec. 31, 2025 - 1.6 million
Sept. 30, 2025 - 1.6 million

REPL

Price: $14.63

52 week price:
1.50
15.71

Earnings Per Share: -3.15 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 354500

Market Capitalization: 1.4 billion

Links: